Related Experiment Videos
Therapeutic effect of sentinel lymphadenectomy in T1 breast cancer
D W Ollila1, M B Brennan, A E Giuliano
1John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, Calif 90404, USA.
Objective:
To evaluate whether the tumor status of the sentinel lymph node (SN) would alter the systemic adjuvant therapy administered to patients with T1 breast cancer.
Design And Patients:
Consecutive breast cancer patients (tumors < or = 2 cm) who underwent successful sentinel lymphadenectomy.
Main Outcome Measures:
Metastatic tumor in the SN, primary tumor size, recommendations for systemic adjuvant therapy before and after histopathologic evaluation of the SN, and actual systemic adjuvant therapy received by the patient.
Results:
Of 142 total patients, 14 had T1a tumors; 35, T1b; and 93, T1c. Recommendations for systemic adjuvant therapy were initially determined solely by primary tumor characteristics and menopausal status. These recommendations were compared with recommendations for systemic adjuvant therapy based on tumor characteristics, menopausal status, and SN status; and then were compared with actual systemic adjuvant therapy received by the patient. Among the 118 patients with T1a, T1b, and favorable (positive estrogen or progesterone receptors and a low S-phase percentage with respect to DNA content) T1c tumors, 15 (37.5%) of 40 premenopausal patients and 20 (25.6%) of 78 postmenopausal patients became candidates for chemotherapy when examination of the SN revealed axillary metastasis; chemotherapy was actually administered to all 15 premenopausal patients but to only 6 postmenopausal patients. In the remaining 24 patients with unfavorable T1c tumors, SN status did not change the recommendation for chemotherapy but may have altered the choice of specific chemotherapeutic agents.
Conclusions:
Identification of tumor-involved SN may alter systemic adjuvant therapy in patients with T1a, T1b, and favorable T1c tumors and may potentially change the type or dose of chemotherapeutic agents given to patients with unfavorable T1c tumors. Surgical axillary staging of the axilla remains an essential part of breast cancer management and should not be abandoned.
Insights
Sentinel lymph node (SN) tumor status significantly impacts systemic adjuvant therapy decisions for early-stage breast cancer patients. This finding underscores the importance of axillary staging in personalized treatment planning.
Area of Science:
- Oncology
- Surgical Pathology
- Breast Cancer Research
Background:
- Sentinel lymph node (SN) biopsy is a standard procedure in breast cancer staging.
- Accurate staging is crucial for determining appropriate systemic adjuvant therapy.
Purpose of the Study:
- To assess if sentinel lymph node (SN) tumor status influences systemic adjuvant therapy in T1 breast cancer patients.
- To evaluate the impact of SN metastasis on treatment recommendations and actual therapy administered.
Main Methods:
- Retrospective analysis of 142 breast cancer patients with tumors <= 2 cm.
- Comparison of systemic adjuvant therapy recommendations before and after SN histopathologic evaluation.
- Analysis of primary tumor characteristics, menopausal status, and SN metastasis.
Main Results:
- SN metastasis altered systemic adjuvant therapy recommendations in 15/40 premenopausal and 20/78 postmenopausal patients with T1a, T1b, and favorable T1c tumors.
- Chemotherapy was administered to all eligible premenopausal patients but only 6 postmenopausal patients.
- For unfavorable T1c tumors, SN status influenced chemotherapy agent choice but not the recommendation.
Conclusions:
- Sentinel lymph node (SN) tumor involvement is a critical factor in tailoring systemic adjuvant therapy for early-stage breast cancer.
- Axillary staging via SN biopsy remains essential for comprehensive breast cancer management.
- SN status can modify treatment intensity and drug selection, especially in favorable T1c tumors.